Serum 14-3-3β protein: a new biomarker in asthmatic patients with acute exacerbation in an observational study.
Serum 14-3-3β protein: a new biomarker in asthmatic patients with acute exacerbation in an observational study.
复制标题
血清 14-3-3 β 蛋白：一项观察性研究中哮喘急性加重患者的新生物标志物
DOI：
10.1186/s13223-021-00608-4
复制
发表时间：
2021-10-09
期刊：
影响因子：
--
通讯作者：
Mo B
中科院分区：
文献类型：
--
作者：
Wang D;Rao L;Cui Y;Tang G;Huang H;Yuan T;Mo B
全身炎症标志物的测定是研究哮喘发病机制、提高哮喘诊断水平的重要方向之一。目前研究发现14-3-3蛋白家族亚型与靶蛋白相互作用参与多种免疫炎症性疾病的发病机制。然而，关于哮喘患者血清酪氨酸3-单加氧酶/酪氨酸5-单加氧酶激活蛋白β（14-3-3β）的研究较少。本研究旨在探讨14-3-3β在哮喘患者中的临床意义。我们招募了54例急性发作期哮喘患者和50例慢性持续性哮喘患者。正常对照组54例。临床特征、临床指标[呼气一氧化氮分数（FeNO）、嗜酸性粒细胞计数、用力肺活量（FVC）、预计FVC百分比（FVC%预测值），一秒用力呼气量（FEV 1），占FEV 1预测值的百分比（FEV1%预测值），测定各组第一秒用力呼气量与用力肺活量比值（FEV 1/FVC）及血清14-3-3β水平，并进行比较。采用斯皮尔曼等级相关系数评价14-3-3β与临床指标的相关性。采用受试者工作特征（ROC）曲线分析14-3-3β的敏感性和特异性。结果显示，中位数哮喘急性发作组血清14-3-3β浓度（ng/mL）（四分位距）（41.18 [33.06-51.76]）明显高于正常对照组哮喘慢性迁延组（25.88 [21.03-34.55]; P < 0.001）。斯皮尔曼相关系数显示，哮喘急性发作组血清14-3-3β水平与FeNO（r = − 0.292，P = 0.032）和外周血嗜酸性粒细胞计数（r = 0.328，P = 0.016）呈正相关，与FEV 1/FVC（r = − 0.293，P = 0.031）呈负相关。同时，慢性持续性哮喘组血清14-3-3β水平与FEV 1呈负相关（r =-0.297，P = 0.036）。哮喘急性发作组与正常对照组的ROC曲线比较，AUC为0.90（95% CI 0.85-0.96），有显著性差异（P < 0.001）。血清14-3-3β蛋白可能成为哮喘急性发作的一个潜在生物标志物。在线版本包含补充材料，可通过10.1186/s13223-021-00608-4获得。
The determination of systemic inflammatory markers is one of the important directions to study the pathogenesis of asthma and improve the diagnosis of asthma. Current studies have found that the 14-3-3 protein family subtypes interact with target proteins to participate in the pathogenesis of a variety of immune inflammatory diseases. However, studies on serum tyrosine3-monooxygenase/tryptophan5-monooxygenase activation protein β (14-3-3β) in asthma are scarce. This study aimed to assess the clinical significance of 14-3-3β in asthmatic patients. We recruited 54 asthmatic patients with acute exacerbation and 50 asthmatic patients with chronic persistent. The normal control group included 54 healthy individuals. Clinical characteristics, clinical indicators [fractional expiratory nitric oxide (FeNO), eosinophil count, forced vital capacity (FVC), percent of predicted FVC (FVC% predicted), forced expiratory volume in one second (FEV1), percent of predicted FEV1 (FEV1% predicted), the ratio of forced expiratory volume in one second to forced vital capacity (FEV1/FVC) and serum 14-3-3β levels were measured to compare among each group. Spearman’s rank correlation coefficient was used to evaluate the correlation between 14-3-3β and clinical indicators. Finally, Receiver-operating characteristic (ROC) curves analysis was used to determine the sensitivity and specificity of 14-3-3β. Our results showed that median (interquartile range) of serum 14-3-3β concentration (ng/mL) in acute exacerbation group of asthma (41.18 [33.06–51.76]) was much higher than that in normal control group (24.99 [17.43–29.91]; P < 0.001) and chronic persistent group of asthma (25.88 [21.03–34.55]; P < 0.001). Spearman’s correlation coefficient shows that the serum 14-3-3β level was positively correlated with FeNO (r = − 0.292, P = 0.032) and peripheral blood eosinophil count (r = 0.328, P = 0.016), and was negatively related to FEV1/FVC (r = − 0.293, P = 0.031) in the acute exacerbation group of asthma. At the same time, the serum 14-3-3β level was also negatively associated with FEV1 (r = − 0.297, P = 0.036) in the chronic persistent group of asthma. ROC curve analysis comparing acute exacerbation group of asthma with normal control group demonstrated a significant (P < 0.001) AUC of 0.90 (95% CI 0.85–0.96). The serum 14-3-3β protein may become a potential biomarker in asthmatic patients with acute exacerbation. The online version contains supplementary material available at 10.1186/s13223-021-00608-4.
登录
查看更多内容
影响因子：
5.6
作者：
Abdrabou, Abdalla;Brandwein, Daniel;Wang, Zhixiang
通讯作者：
Wang, Zhixiang
影响因子：
24.3
作者：
Miller, MR;Hankinson, J;Wanger, J
通讯作者：
Wanger, J
影响因子：
76.2
作者：
Price, David B.;Rigazio, Anna;Pavord, Ian D.
通讯作者：
Pavord, Ian D.
DOI：
10.1016/j.jaci.2017.10.029
发表时间：
2018-07
期刊：
The Journal of allergy and clinical immunology
影响因子：
--
作者：
Cascio S;Medsger TA Jr;Hawse WF;Watkins SC;Milcarek C;Moreland LW;Lafyatis RA;Fuschiotti P
通讯作者：
Fuschiotti P
影响因子：
2.7
作者：
Chen, Xingyuan;Chen, Qiu
通讯作者：
Chen, Qiu